Vident Advisory LLC Sells 7,018 Shares of Prestige Consumer Healthcare Inc. $PBH

Key Points

• Vident Advisory LLC reduced its stake in Prestige Consumer Healthcare by 62.4%, selling 7,018 shares and now holds 4,236 shares valued at $364,000.
• Prestige Consumer Healthcare reported a miss on earnings with $0.95 EPS for the last quarter, below the analysts' expectation of $1.01, alongside a revenue drop of 6.6% year-over-year.
• Analysts have mixed opinions on the stock, with ratings ranging from "strong sell" to "buy," and a target price averaging $93.33.

Vident Advisory LLC lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 62.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,236 shares of the company's stock after selling 7,018 shares during the quarter. Vident Advisory LLC's holdings in Prestige Consumer Healthcare were worth $364,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter worth approximately $84,932,000. Invesco Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 24.7% in the first quarter. Invesco Ltd. now owns 1,321,800 shares of the company's stock worth $113,635,000 after buying an additional 261,537 shares in the last quarter. GAMMA Investing LLC raised its stake in Prestige Consumer Healthcare by 11,580.3% in the first quarter. GAMMA Investing LLC now owns 161,538 shares of the company's stock valued at $13,887,000 after purchasing an additional 160,155 shares in the last quarter. Neumeier Poma Investment Counsel LLC purchased a new position in shares of Prestige Consumer Healthcare during the first quarter worth approximately $8,713,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Prestige Consumer Healthcare during the 4th quarter valued at $7,778,000. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Stock Down 2.6%

Shares of PBH traded down $1.71 during midday trading on Friday, reaching $63.31. 560,980 shares of the company were exchanged, compared to its average volume of 569,221. Prestige Consumer Healthcare Inc. has a 1-year low of $62.95 and a 1-year high of $90.04. The company has a market cap of $3.12 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 2.06 and a beta of 0.46. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The stock has a 50-day moving average price of $70.53 and a 200-day moving average price of $79.18.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing analysts' consensus estimates of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The firm had revenue of $249.53 million during the quarter, compared to analyst estimates of $260.71 million. During the same quarter last year, the company earned $0.90 earnings per share. The business's revenue for the quarter was down 6.6% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on PBH shares. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $105.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, August 8th. Zacks Research downgraded Prestige Consumer Healthcare from a "hold" rating to a "strong sell" rating in a research report on Thursday, September 4th. Finally, Wall Street Zen cut Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of "Hold" and an average target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.